Contribution of efflux pump activity to the delivery of pulmonary therapeutics

被引:20
作者
Hamilton, KO
Yazdanian, MA
Audus, KL
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Simons Labs, Lawrence, KS 66047 USA
[2] Boehringer Ingelheim Pharmaceut Inc, Dept Pharmaceut, Ridgefield, CT 06877 USA
关键词
D O I
10.2174/1389200023338170
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To date, there are few in vitro models of the human lung that have been used to characterize multidrug resistant (MDR) efflux pump activity. It is expected that the presence of these protein transporter molecules, such as P-glycoprotein (Pgp) and the multidrug resistance protein associated protein-1 (MRP1), might play a role in limiting drug absorption through the pulmonary epithelium, as has been reported for other epithelial drug delivery barriers such as the intestine and brain. To date, the exact role of the lung resistance related protein (LRP) in MDR is unclear. In this article, we have summarized the biochemistry, function and in vitro/in vivo modulation of Pgp and MRP1. These topics are discussed in light of pulmonary delivery of therapeutic agents, with particular emphasis being placed on the bronchial region of human airways.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 140 条
[31]  
Forbes Ben, 2000, Pharmaceutical Science and Technology Today, V3, P18, DOI 10.1016/S1461-5347(99)00231-X
[32]   Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery [J].
Foster, KA ;
Avery, ML ;
Yazdanian, M ;
Audus, KL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 208 (1-2) :1-11
[33]   Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism [J].
Foster, KA ;
Oster, CG ;
Mayer, MM ;
Avery, ML ;
Audus, KL .
EXPERIMENTAL CELL RESEARCH, 1998, 243 (02) :359-366
[34]   Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium [J].
Foster, KA ;
Yazdanian, M ;
Audus, KL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (01) :57-66
[35]   Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies [J].
Fracasso, PM ;
Westerveldt, P ;
Fears, CA ;
Rosen, DM ;
Zuhowski, EG ;
Cazenave, LA ;
Litchman, M ;
Egorin, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) :1124-1134
[36]  
Fukumoto M, 1999, CANCER-AM CANCER SOC, V86, P1470, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1470::AID-CNCR13>3.3.CO
[37]  
2-J
[38]  
GAO, 1997, ANTICANCER RES, V17, P3073
[39]   Multidrug resistance protein -: Identification of regions required for active transport of leukotriene C4 [J].
Gao, M ;
Yamazaki, M ;
Loe, DW ;
Westlake, CJ ;
Grant, CE ;
Cole, SPC ;
Deeley, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) :10733-10740
[40]   THE LEUKOTRIENE LTD(4) RECEPTOR ANTAGONIST MK571 SPECIFICALLY MODULATES MRP ASSOCIATED MULTIDRUG-RESISTANCE [J].
GEKELER, V ;
ISE, W ;
SANDERS, KH ;
ULRICH, WR ;
BECK, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 208 (01) :345-352